SCHEMBL948435

SCHEMBL948435

CCCC(=O)NCCC(=O)OCc1ncc2n1C(=O)N(C1CCN(C(=O)OC(C)(C)C)CC1)C2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.37
F10 P00742 2/20 0.37
TP53 P04637 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
DDB1 Q16531 2/20 0.34
CRBN Q96SW2 2/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
LMNA P02545 2/20 0.34
THRB P10828 1/20 0.34
HCAR1 Q9BXC0 1/20 0.34
BCDIN3D Q7Z5W3 1/20 0.34
FPR2 P25090 1/20 0.34
NR3C1 P04150 1/20 0.34
ACACB O00763 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL947848 0.95 F2 (0.35) F2F10TP53GPR119L3MBTL1
SCHEMBL948472 0.91 F10 (0.38) F2F10TP53GPR119L3MBTL1
SCHEMBL949369 0.87 F2 (0.37) F2F10TP53GPR119L3MBTL1
SCHEMBL948437 0.86 L3MBTL1 (0.41) F2F10TP53GPR119L3MBTL1
SCHEMBL947773 0.85 F2 (0.36) F2F10TP53GPR119MEN1
SCHEMBL948379 0.85 F10 (0.37) F2F10TP53GPR119MEN1
SCHEMBL950561 0.84 F10 (0.38) F2F10TP53GPR119MEN1
SCHEMBL949039 0.83 F10 (0.38) F2F10TP53GPR119DDB1
SCHEMBL948337 0.83 F10 (0.37) F2F10TP53GPR119DDB1
SCHEMBL948926 0.82 F10 (0.38) F2F10TP53GPR119DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 US disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 F2 2/4885F10 545/4885TP53 4661/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 F2 1/4885F10 490/4885TP53 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.